Urogen Pharma (NASDAQ:URGN) Shares Gap Down – What’s Next?

Shares of Urogen Pharma (NASDAQ:URGN – Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $26.18, but opened at $24.00. Urogen Pharma shares last traded at $25.5580, with a volume of 311,241 shares trading hands.

Wall Street Analysts Forecast Growth

URGN has been the topic of a number of research reports. Jefferies Financial Group reissued a “buy” rating and issued a $56.00 target price on shares of Urogen Pharma in a research note on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday, October 15th. Oppenheimer set a $60.00 price target on Urogen Pharma in a research report on Thursday, November 5th. TD Cowen increased their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, UBS Group reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Thursday, November 5th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.38.

View Our Latest Research Report on Urogen Pharma

Urogen Pharma Stock Up 7.7%

The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -21.42 and a beta of 1.68. The company’s 50-day moving average is $37.00 and its 200-day moving average is $31.67.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14). The business had revenue of $89.00 million for the quarter, compared to the consensus estimate of $89.92 million. Sell-side analysts anticipate that Urogen Pharma will post -0.36 EPS for the current year.

Insider Transactions at Urogen Pharma

In other news, insider Mark Schoenberg sold 871 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total transaction of $37,383.32. Following the sale, the insider owned 59,882 shares of the company’s stock, valued at approximately $2,570,135.44. The trade was a 1.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the sale, the general counsel directly owned 53,141 shares in the company, valued at approximately $2,260,618.14. The trade was a 2.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 65,269 shares of company stock worth $3,037,646 in the last 90 days. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Sterling Capital Management LLC increased its stake in Urogen Pharma by 442.1% in the third quarter. Sterling Capital Management LLC now owns 1,339 shares of the company’s stock valued at $54,000 after purchasing an additional 1,092 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Urogen Pharma by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,919 shares of the company’s stock worth $361,000 after buying an additional 1,165 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Urogen Pharma during the 2nd quarter worth approximately $66,000. Quantbot Technologies LP acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $78,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Urogen Pharma in the 3rd quarter valued at $101,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

(Get Free Report)

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.

Further Reading

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.